Similarly, EGCG was observed to reduce GLUT1 expression in breast cancer and pancreatic cancer, although the mechanism may be attributed to its inhibitory effect on HIF-1α, which is vital for regulating the genes encoding GLUT and ameliorating the activities of glycolytic enzymes (176, 177). Here, SLC2A1 is linked to breast carcinoma.